TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06771258

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Light (PDT)
Description: Red LED light

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Light (PDT)
Description: Red LED light

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Light (PDT)
Description: Red LED light

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Light (PDT)
Description: Red LED light
Study: NCT06773624

Intervention type: OTHER
Group type: OTHER
Intervention: PET/CT-enterography with 68Ga-DOTATOC
Description: Patients underwent to PET/CT-enterography with 68Ga-DOTATOC
Study: NCT06774742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HAFS Supplementation
Description: 1 capsule of HAFS per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule of placebo per day
Study: NCT06774456

Intervention type: DEVICE
Group type: OTHER
Intervention: instrumented 3D serious game (BE API 3.0)
Description: It is composed of bimanual tasks integrated into a game scenario. The child is first equipped with markers on the upper limb (UL) and trunk (3D motion analysis and electromyography), and he/she can then play the game. There are several tasks ('piloting missions') to evaluate specific UL movements. The UL movements are recorded when the child is playing. The instruments of the set-up (wheel, turbo, etc.) are connected to the game to play and can also be used as measurements (grip strength, etc.). The markers are then removed. The total duration of the game is about 30-45 minutes, including placing/removing markers and the game.

Intervention type: DEVICE
Group type: OTHER
Intervention: instrumented 3D serious game (BE API 3.0)
Description: It is composed of bimanual tasks integrated into a game scenario. The child is first equipped with markers on the upper limb (UL) and trunk (3D motion analysis and electromyography), and he/she can then play the game. There are several tasks ('piloting missions') to evaluate specific UL movements. The UL movements are recorded when the child is playing. The instruments of the set-up (wheel, turbo, etc.) are connected to the game to play and can also be used as measurements (grip strength, etc.). The markers are then removed. The total duration of the game is about 30-45 minutes, including placing/removing markers and the game.
Study: NCT06771284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Function-based assessment and intervention
Description: This intervention will be implemented by the caregiver. The intervention will consist of teaching the child an alternative, appropriate skill (usually communication) to replace the problem behavior. The caregiver will provide reinforcement for the appropriate skill and no reinforcement (i.e., extinction) following problem behavior. The caregiver will also learn and use general strategies for teaching social-emotional skills (e.g., setting appropriate rules) as part of the intervention.
Study: NCT06772272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) used to treat anemia. Participants in the Roxadustat group will receive 100mg of Roxadustat orally three times per week for three weeks (two weeks prior to surgery and one week post-surgery). The dosage may be adjusted based on hemoglobin levels during the perioperative period: if hemoglobin rises above 150g/L, the drug will be stopped; if hemoglobin increases by more than 20g/L from baseline but is still below 130g/L, the dosage will be reduced to 70mg; if hemoglobin drops by more than 20g/L from baseline, the dosage will be increased to 120mg.
Study: NCT06774976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-week Evidence-Based Neck Resistance Training Program
Description: See arm/group description.
Study: NCT06775080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol (beta-blocker used treat high blood pressure)
Description: Enrolled patients began receiving propranolol alone orally twice daily (10 mg bid) 10-14 days prior to surgery, and after 3 days of treatment, the dose of propranolol was increased to 20 mg bid daily until the day of surgery if the following three predefined criteria were met: systolic blood pressure greater than 90 mmHg, heart rate greater than 60 bpm, and no significant symptoms (e.g., syncope, insomnia, fatigue). The patient continues to be treated from 1 week after surgery.From 1 week after surgery, patients continue propranolol for 3 weeks. Patients will be monitored daily for symptoms, blood pressure, and heart rate and will be followed for observation at 6, 12, and 24 months after surgery until disease progression or clinical death, unless intolerable toxicity occurs and the patient refuses to continue treatment. The efficacy and safety of the preoperative propranolol β-blockade regimen in patients with gastrointestinal tract tumors was evaluated using the study objectives in S
Study: NCT06772701

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mini International Neuropsychiatric Interview
Description: Fathers have Mini International Neuropsychiatric Interview, the standard diagnostic tool for post-natal depression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EPDS book
Description: PH-Q9, EPDS and socio-demographic questionnaires are completed online at inclusion and 6 to 8 weeks after the birth of child.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPDS book
Description: PH-Q9, EPDS and socio-demographic questionnaires are completed online at inclusion and 6 to 8 weeks after the birth of child.
Study: NCT06771908

Intervention type: DIAGNOSTIC_TEST
Intervention: Conjunctival Swab
Description: CFU/ml by bacterial species before and after prophylaxis.
Study: NCT06773195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: There are 3 planned dose levels of ulixertinib(450 mg BID, 300 mg BID, or 150 mg BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib for 28 day cycles.
Study: NCT06772103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: self-locking biceps tenodesis
Description: The LHB tendon is detached from its origin at the level of the superior labrum. This technique supports the self-locking mechanism of the LHB tendon in the bicipital groove by detaching the tendon from the Y-shaped superior glenoid, including the superior labrum. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biceps Tenodesis with 360 Suture anchor
Description: The LHB tendon is detached from its origin and sutured. Next, the LHB tendon is fixed in the bicipital groove using a 360-loop tenodesis technique with the Knotless FiberTak® biceps implant system. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
Study: NCT04762186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human SARS-CoV 2 specific T lymphocytes
Description: In dose level one, SARS-CoV-2 infected patients will receive 1,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In dose level two SARS-CoV-2 infected patients will receive 5,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In parallel, all patients will receive the current SoC treatment for COVID-19.
Study: NCT05156008

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound-guided vascular access
Description: Patients in this arm will have peripheral venous cannula inserted under realtime ultrasound guidance. Out of plane technique (in plane technique if too deep when tip of the needle is on vessel wall) used by experienced physicians in UGVA. Out of plane technique strictly used in step by step manner. That means moving probe with the tip of the needle to always locate its exact position, all the way into the vein. All performed insertions are carried out by skilled operators in UGVA with out of plane technique. Just before surgery in block room.
Study: NCT05776992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xbox virtual reality games
Description: X-box balance evaluation was implemented in a completely dark and isolated room specially prepared for this treatment and evaluation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodex balance training
Description: the Biodex Balance System SD has been designed to meet the needs of everyone looking to improve balance, increase agility, develop muscle tone and treat a wide variety of pathologies.
Study: NCT06209242

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous pinning
Description: Using k- wire percutaneous pinning with local anesthesia with one-day surgery protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cast immobilization
Description: Using sugar tong slab and then replace to short arm casting within 1 week
Study: NCT06478290

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: curcumin, omega-3, and vitamin D (COD)
Description: Combination of curcumin, omega-3, and vitamin D supplements (COD). Acumin™Turmeric Complex/Dr. D's Ultra BioTurmeric: 500 mg/day (oral, 2 tablets taken by mouth), Vitamin D: 2500 IU/day (oral, 1 tablet taken by mouth), Omega-3: 900 mg day (oral, 1 tablet taken by mouth)
Study: NCT06197204

Intervention type: OTHER
Intervention: Blood sampling
Description: * at first visit in the reference center~* at each follow-up visit ( once a year)~* before and after specific treatment~* in case of flare

Intervention type: OTHER
Intervention: Biopsy
Description: In case of flare

Intervention type: OTHER
Intervention: Blood sampling
Description: Once at inclusion visit
Study: NCT05496764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: we planned to inject steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in group A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: we planned to inject steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in group A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Injection
Description: inject10 ml glucose 5% into the carpal tunnel in group B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Injection
Description: inject10 ml glucose 5% into the carpal tunnel in group B
Study: NCT05917340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose rifampicin (25mg/kg)
Description: Given for 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose rifampicin (25mg/kg)
Description: Given for 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: Given for 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: Given for 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg
Description: Given for 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Given for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Given for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Given for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Given for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid
Description: Tapering dose of dexamethasone or prednisolone upto 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid
Description: Tapering dose of dexamethasone or prednisolone upto 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Standard dose for 4 months after the initial treatment with high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Standard dose for 4 months after the initial treatment with high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRZE
Description: 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRE
Description: 7-10 months as per TB program guidelines
Study: NCT05457959

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Dendritic Cell Tumor Peptide Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Tumor Peptide Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Tumor Peptide Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Tumor Peptide Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given ID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given ID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Poly ICLC
Description: Given IM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Poly ICLC
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given IM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Poly ICLC
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given IM

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Resection
Description: Undergo standard of care surgical resection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Resection
Description: Undergo standard of care surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo standard of care surgical resection
Study: NCT06525519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATLG
Description: 5 mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATLG
Description: 7.5mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
Study: NCT05709613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a chest compressions' feedback device
Description: The participants will have access to a chest compressions' feedback device
Study: NCT06214884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness for All
Description: Experimental:~The MFA will take place in a group setting with 10-15 participants per cluster. Due to participants' convenience, the delivery mode of each intervention session would be conducted online. At the end of session, they will be provided the task and supplementary materials (e-book, short audio, and video) to be apply after the session. The modules will be delivered by two trainees. Both trainees have received the certificates from the mindfulness-based strategic awareness training course. Participants in the intervention group will be joining the modules for 5 sessions weekly for 60-minute/session. Details on the modules can be referred in the Supplement material.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness for All
Description: Experimental:~The MFA will take place in a group setting with 10-15 participants per cluster. Due to participants' convenience, the delivery mode of each intervention session would be conducted online. At the end of session, they will be provided the task and supplementary materials (e-book, short audio, and video) to be apply after the session. The modules will be delivered by two trainees. Both trainees have received the certificates from the mindfulness-based strategic awareness training course. Participants in the intervention group will be joining the modules for 5 sessions weekly for 60-minute/session. Details on the modules can be referred in the Supplement material.
Study: NCT05324189

Intervention type: DIAGNOSTIC_TEST
Intervention: Referable versus Non Referable Diabetic Retinopathy diagnostic test
Description: Artificial intelligence read reports Referable versus Non Referable Diabetic Retinopathy

Intervention type: DIAGNOSTIC_TEST
Intervention: Referable versus Non Referable Diabetic Retinopathy diagnostic test
Description: Artificial intelligence read reports Referable versus Non Referable Diabetic Retinopathy
Study: NCT06437171

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Omalizumab
Description: Omalizumab dose and frequency based on baseline subject weight and total IgE
Study: NCT06550648

Intervention type: PROCEDURE
Intervention: Right Heart Catheterization (Swan Ganz Catheter)
Description: Swan Ganz Catheter only for PAH patients, Using the swan ganz and pressure transducer

Intervention type: PROCEDURE
Intervention: Right Heart Catheterization (Swan Ganz Catheter)
Description: Swan Ganz Catheter only for PAH patients, Using the swan ganz and pressure transducer
Study: NCT05545735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Antibiotic Therapy
Description: Antibiotics will be administered as per the standard of care orally via tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Antibiotic Therapy
Description: Antibiotics will be administered as per the standard of care orally via tablet
Study: NCT06026397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK10
Description: Participants will be randomized to receive oral suspension of SK10 powder, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK10
Description: Participants will be randomized to receive oral suspension of SK10 powder, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK10
Description: Participants will be randomized to receive oral suspension of SK10 powder, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be randomized to receive oral suspension of placebo, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be randomized to receive oral suspension of placebo, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be randomized to receive oral suspension of placebo, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
Study: NCT05836623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled CB307
Description: CB307 radiolabelled with 89-Zirconium (89Zr CB307): drug product is formulated at a concentration of 1 mg/mL (37 MBq)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled CB307
Description: CB307 radiolabelled with 89-Zirconium (89Zr CB307): drug product is formulated at a concentration of 1 mg/mL (37 MBq)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB307
Description: Trispecific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB307
Description: Trispecific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
Study: NCT06430489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: inhaled nitrous oxide (1 hour at 50% concentration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical air
Description: inhaled medical air (1 hour)
Study: NCT05919134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dentoblis
Description: dissolve the tablets in the mouth once a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dissolve the tablets in the mouth once a day for 4 weeks
Study: NCT06033378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure elevation
Description: Increasing systemic blood pressure for measurement of cerebral blood flow changes
Study: NCT05673122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant(Flotecno)
Description: The implants It has a tapered body design and Sandblasting with Large grit that facilitates the osseointergration process.~made in Italy Flotecno srl via.Turati,38 20121 MILANO (Italia)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant(Flotecno)
Description: The implants It has a tapered body design and Sandblasting with Large grit that facilitates the osseointergration process.~made in Italy Flotecno srl via.Turati,38 20121 MILANO (Italia)
Study: NCT01311323

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Percutaneous Coronary Intervention with contemporary drug eluting stent, fractional flow reserve or iFR measurement and optimisation with intravascular imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: Coronary Artery Bypass Graft
Study: NCT04754295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-Directed Therapy
Description: Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STANDARD
Description: Administration of fluids and vasoactive drugs guided by standard vital signs monitoring